{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:35:05Z","timestamp":1793237705015,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004599","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacadv.2026.103019","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:10:00Z","timestamp":1784765400000},"page":"103019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Delayed Diagnosis of Transthyretin Cardiac Amyloidosis Is Associated With Heart Failure Hospitalizations and Mortality"],"prefix":"10.1016","volume":"5","author":[{"given":"Gabriela","family":"Spencer-Bonilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-8948","authenticated-orcid":false,"given":"Anubodh Sunny","family":"Varshney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-0723","authenticated-orcid":false,"given":"Fatima","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia A.","family":"Papas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Venditto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jacadv.2026.103019_bib1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103019_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of delayed diagnosis and misdiagnosis for patients with transthyretin Amyloid Cardiomyopathy (ATTR-CM): a targeted literature review","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol Ther"},{"issue":"8","key":"10.1016\/j.jacadv.2026.103019_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11936-019-0743-2","article-title":"Emerging therapies for transthyretin cardiac amyloidosis","volume":"21","author":"Alexander","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"22","key":"10.1016\/j.jacadv.2026.103019_bib4","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103019_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jacc.2025.10.021","article-title":"Delayed diagnosis of transthyretin amyloid cardiomyopathy in the Veterans Health administration","volume":"87","author":"Spencer-Bonilla","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103019_bib6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103019_bib7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103019_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004966","article-title":"Comparison of expert adjudicated coronary heart disease and cardiovascular disease mortality with the national death index: results from the REasons for geographic and racial differences in stroke (REGARDS) study","volume":"6","author":"Olubowale","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jacadv.2026.103019_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.010718","article-title":"Equity in the setting of heart failure diagnosis: an analysis of differences between and within clinician practices","volume":"17","author":"Gupta","year":"2024","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103019_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"18","key":"10.1016\/j.jacadv.2026.103019_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026308","article-title":"Modeling the cost and health impacts of diagnostic strategies in patients with suspected transthyretin cardiac amyloidosis","volume":"11","author":"Ge","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2026.103019_bib12","series-title":"The centers for disease control and prevention and agency for toxic substances and disease registry social vulnerability index","year":"2025"},{"issue":"14","key":"10.1016\/j.jacadv.2026.103019_bib13","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why test for proportional hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103019_bib14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jacc.2025.10.021","article-title":"Delayed diagnosis of transthyretin amyloid cardiomyopathy in the Veterans Health administration","volume":"87","author":"Spencer-Bonilla","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2026.103019_bib15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamacardio.2026.0833","article-title":"Timeliness of transthyretin cardiac amyloidosis diagnosis in the medicare population","volume":"11","author":"Spencer-Bonilla","year":"2026","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103019_bib16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13023-022-02425-3","article-title":"Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis","volume":"17","author":"Jang","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"10.1016\/j.jacadv.2026.103019_bib17","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103019_bib18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jaccao.2024.12.005","article-title":"A multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy","volume":"7","author":"Masri","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103019_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","article-title":"Diagnostic delay in wild type transthyretin cardiac amyloidosis - a clinical challenge","volume":"304","author":"Ladefoged","year":"2020","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.jacadv.2026.103019_bib20","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103019_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jacadv.2026.103019_bib22","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/ejhf.3330","article-title":"Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction","volume":"26","author":"Drachman","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103019_bib23","article-title":"Treatment of transthyretin amyloid cardiomyopathy with tafamidis 61 mg - real-world data from a tertiary center (TAFA-CRUZ study)","author":"Carvalho","year":"2026","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103019_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.102470","article-title":"Atrial Fibrillation\/Flutter in Transthyretin cardiac amyloidosis: prevalence, incidence, clinical predictors, and effect of tafamidis","volume":"5","author":"Chan","year":"2026","journal-title":"JACC Adv"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103019_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40256-022-00563-4","article-title":"Real-World characteristics of patients with wild-type transthyretin amyloid cardiomyopathy: an analysis of electronic healthcare records in the United States","volume":"23","author":"Bhambri","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103019_bib26","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s00392-026-02848-z","article-title":"Current treatment decisions in cardiac transthyretin amyloidosis: a multicentre analysis","volume":"115","author":"Lavall","year":"2026","journal-title":"Clin Res Cardiol"},{"issue":"21","key":"10.1016\/j.jacadv.2026.103019_bib27","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1001\/jama.2024.2868","article-title":"Addressing health disparities-the case for variant transthyretin cardiac amyloidosis grows stronger","volume":"331","author":"Maurer","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103019_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103019_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26004400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26004400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:28:23Z","timestamp":1793237303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26004400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2772963X26004400"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103019","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed Diagnosis of Transthyretin Cardiac Amyloidosis Is Associated With Heart Failure Hospitalizations and Mortality","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103019"}}